Side-effects of resveratrol in HepG2 cells: Reduced pten and increased bcl-xl mRNA expression

Zheng,Min; Chen,Ruifu; Zhong,Hongyuan; Lin,Qiuyan; Wang,Xiaoqin; Zhao,Zhiwei; Xie,Linna

doi:10.3892/mmr.2012.1077

Side-effects of resveratrol in HepG2 cells: Reduced pten and increased bcl-xl mRNA expression

Authors:
- Min Zheng
- Ruifu Chen
- Hongyuan Zhong
- Qiuyan Lin
- Xiaoqin Wang
- Zhiwei Zhao
- Linna Xie
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350108, P.R. China, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350108, P.R. China, Department of Bioengineering, Fujian Vocational College of Bioengineering, Fuzhou 350007, P.R. China
Published online on: September 12, 2012 https://doi.org/10.3892/mmr.2012.1077
Pages: 1367-1370

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resveratrol is a natural compound present in red grapes and red wine, and is often consumed in the human diet. The chemopreventive and chemotherapeutic potential of resveratrol in hepatocellular carcinoma (HCC), one of the most common types of liver cancer, has received much attention in recent years. However, the side-effects of resveratrol stimulation are of concern due to the high doses administered to humans. This study investigated the effects of resveratrol on the mRNA expression of pten and bcl-xl in HepG2 cells using semi‑quantitative and quantitative PCR. This study demonstrated that 200 µmol/l resveratrol stimulation for 12 h resulted in the inhibition of HepG2 proliferation, reduced pten and increased bcl-xl mRNA expression. The data suggest that (a) the anticancer mechanism of resveratrol does not involve the induction of pten and inhibition of bcl-xl expression and (b) resveratrol induces a cellular self-protection response, which underlies the cellular chemoresistance against resveratrol in HepG2 cells.

View Figures

View References

1	Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218–220. 1997. View Article : Google Scholar : PubMed/NCBI
2	Baur JA and Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 5:493–506. 2006. View Article : Google Scholar : PubMed/NCBI
3	Santandreu FM, Valle A, Oliver J and Roca P: Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cell Physiol Biochem. 28:219–228. 2011. View Article : Google Scholar : PubMed/NCBI
4	Weng CJ, Wu CF, Huang HW, Wu CH, Ho CT and Yen GC: Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J Agric Food Chem. 58:2886–2894. 2010. View Article : Google Scholar : PubMed/NCBI
5	Yan F, Tian XM and Ma XD: Effects of resveratrol on growth inhibition and gap-junctional intercellular communication of HepG2 cells. Nan Fang Yi Ke Da Xue Xue Bao. 26:963–966. 2006.(In Chinese).
6	Ciolino HP, Daschner PJ and Yeh GC: Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 58:5707–5712. 1998.PubMed/NCBI
7	Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR and Zhou XH: Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun. 380:644–649. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lu CC and Chen JK: Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. J Cell Physiol. 223:343–351. 2010.PubMed/NCBI
9	Yu HB, Zhang HF, Zhang X, et al: Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-κB-mediated mechanism. Hepatogastroenterology. 57:1241–1246. 2010.PubMed/NCBI
10	Parekh P, Motiwale L, Naik N and Rao KV: Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol. 63:167–173. 2011. View Article : Google Scholar : PubMed/NCBI
11	Hiroto Y, Tadokoro K, Tsuda T, et al: Resveratrol, a phytoestrogen found in red wine, down-regulates protein S expression in HepG2 cells. Thromb Res. 127:e1–7. 2011. View Article : Google Scholar : PubMed/NCBI
12	Ma XD, Yan F, Ma AD and Wang HJ: Resveratrol induces HepG2 cell apoptosis by depolarizing mitochondrial membrane. Nan Fang Yi Ke Da Xue Xue Bao. 26:406–408. 4132006.(In Chinese).
13	Zhou R, Fukui M, Choi HJ and Zhu BT: Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection. Br J Pharmacol. 158:462–474. 2009. View Article : Google Scholar : PubMed/NCBI
14	Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
15	Chappell WH, Steelman LS, Long JM, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2:135–164. 2011.PubMed/NCBI
16	Chu EC and Tarnawski AS: PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit. 10:RA235–241. 2004.PubMed/NCBI
17	Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
18	Carracedo A, Alimonti A and Pandolfi PP: PTEN level in tumor suppression: how much is too little? Cancer Res. 71:629–633. 2011. View Article : Google Scholar : PubMed/NCBI
19	Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
20	Castilla C, Congregado B, Chinchon D, Torrubia FJ, Japon MA and Saez C: Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology. 147:4960–4967. 2006. View Article : Google Scholar : PubMed/NCBI
21	Hameed DA, Abdel Raheem AM, Mosad E, Hammouda HM, Kamel NA and Abdel Aziz MA: Bcl-XL and Bcl-2 expression in bilharzial squamous cell carcinoma of the urinary bladder: which protein is prognostic? Urology. 72:374–378. 2008. View Article : Google Scholar : PubMed/NCBI
22	Watanabe J, Kushihata F, Honda K, et al: Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery. 135:604–612. 2004. View Article : Google Scholar : PubMed/NCBI
23	Farina A, Ferranti C and Marra C: An improved synthesis of resveratrol. Nat Prod Res. 20:247–252. 2006. View Article : Google Scholar : PubMed/NCBI
24	Trantas E, Panopoulos N and Ververidis F: Metabolic engineering of the complete pathway leading to heterologous biosynthesis of various flavonoids and stilbenoids in Saccharomyces cerevisiae. Metab Eng. 11:355–366. 2009. View Article : Google Scholar : PubMed/NCBI
25	Athar M, Back JH, Tang X, et al: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
26	Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL and Rankin GO: Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr. 136:2542–2546. 2006.PubMed/NCBI
27	Wenzel E, Soldo T, Erbersdobler H and Somoza V: Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res. 49:482–494. 2005. View Article : Google Scholar : PubMed/NCBI
28	Nguyen AV, Martinez M, Stamos MJ, et al: Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res. 1:25–37. 2009.
29	Boocock DJ, Faust GE, Patel KR, et al: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 16:1246–1252. 2007. View Article : Google Scholar : PubMed/NCBI
30	Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E and Castanas E: Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest and NOS activation. Biochim Biophys Acta. 1760:1657–1666. 2006. View Article : Google Scholar : PubMed/NCBI